

## Research Article

# The Characterization of OXA-232 Carbapenemase-Producing ST437 *Klebsiella pneumoniae* in China

Xingbei Weng <sup>1,2</sup>, Qiucheng Shi <sup>3,4</sup>, Sheng Wang <sup>1,2</sup>, Yubo Shi <sup>1,2</sup>, Dinghe Sun <sup>1,2</sup>, and Yunsong Yu <sup>3,4</sup>

<sup>1</sup>Department of Laboratory Medicine, Ningbo Hospital, Zhejiang University School of Medicine, Ningbo, China

<sup>2</sup>Department of Laboratory Medicine, Ningbo First Hospital, Ningbo, China

<sup>3</sup>Department of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China

<sup>4</sup>Key Laboratory of Microbial Technology and Bioinformatics of Zhejiang Province, Hangzhou, China

Correspondence should be addressed to Yunsong Yu; [yvys119@zju.edu.cn](mailto:yvys119@zju.edu.cn)

Received 23 March 2020; Revised 24 May 2020; Accepted 13 June 2020; Published 8 July 2020

Academic Editor: Luis C. M. Antunes

Copyright © 2020 Xingbei Weng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Carbapenem-resistant *Klebsiella pneumoniae* (CRKP) was epidemic around the world and become a global threat to public health. The most important carbapenem-resistant mechanism is producing carbapenemases, especially *Klebsiella pneumoniae* carbapenemase (KPC), which is prevalent in the international clonal complex CC11. The high-risk multidrug-resistant CC11 is widespread worldwide, and KPC-producing and (New Delhi metallo) NDM-producing strains had been reported in this clonal complex before; moreover, cases with the CC11 strain faced more severe forms of drug resistance and treatment challenges than other clonal complexes. In this study, we identified an OXA-232-producing ST437 *Klebsiella pneumoniae* isolate in China, which belonged to CC11. The isolate was resistant to  $\beta$ -lactams, aminoglycosides, and fluoroquinolones but susceptible to fosfomycin, tigecycline, and colistin. The *bla*<sub>OXA-232</sub> gene was located on a 6141 bp ColKP3-type nonconjugative plasmid, and the plasmid was transformed by chemical transformation successfully. This is the first report of OXA-232-producing ST437 *K. pneumoniae* in China, a new clone of high-risk multidrug-resistant CC11.

## 1. Introduction

With the spread of carbapenemase genes, the emergence and dissemination of carbapenem-resistant *Klebsiella pneumoniae* (CRKP) is an escalating global threat. The most important carbapenem-resistant mechanism is producing carbapenemases, which includes KPC, NDM, VIM, IMP, and OXA-48-like. A nationwide survey conducted in China showed that acquisition of two carbapenemase genes, *bla*<sub>KPC-2</sub> and *bla*<sub>NDM</sub>, was responsible for phenotypic resistance in 90% of the CRE strains tested (58% and 32%, respectively), among which several major strain types, such as ST11 of *K. pneumoniae*, were identified [1]. Currently, local clonal disseminations of OXA-48-type carbapenemases in China have been reported [2–4], but we are short of precise data concerning the epidemiology of this carbapenemase.

OXA-48-type carbapenemases were first identified in 2001 [5] and characterized by low level of carbapenem resistance. To date, 11 OXA-48-type carbapenemases have been described: OXA-48, OXA-162, OXA-181, OXA-204, OXA-232, OXA-244, OXA-245, OXA-247, OXA-436, OXA-484, and OXA-519. But OXA-163 and OXA-405 hydrolyze the extended-spectrum cephalosporins and show limited activities against the carbapenems. Moreover, other OXA-48-variants such as OXA-252, OXA-438, OXA-439, OXA-505, OXA-517, OXA-566, and OXA-567 are listed only in GenBank, and it is currently uncertain if these enzymes have carbapenemase activities [6]. OXA-232 is part of OXA-48-type variants and firstly identified from three patients transferred from India to France in 2011, which differed from OXA-48 by five amino acid substitutions and was located on a 6141 bp ColE-type nonconjugative plasmid [7].

Clonal complex 11 (CC11) denotes the STs differed from ST11 by one housekeeper gene, including ST11, ST258, ST340, ST437, ST757, ST855, and others. CC11 is an epidemic *K. pneumoniae* clonal complex [1], and cases with the CC11 strain faced more severe forms of drug resistance and treatment challenges than other clonal complexes [8]. KPC-producing [1] and NDM-producing [9] CC11 have been reported in China, and no one reported OXA-48-type-producing CC11 clone in China although a clonal dissemination of OXA-48-producing ST147 and ST383 [4] as well as two clonal disseminations of OXA-232-producing ST15 have been reported in China [2, 3]. This is the first report of OXA-232-producing ST437 *K. pneumoniae* in China, a new clone of high-risk multidrug-resistant CC11. The aim of this study was to determine the antimicrobial resistance profile, and identify the carrier plasmid and the flanking region of the *bla*<sub>OXA-232</sub> gene.

## 2. Materials and Methods

**2.1. Isolation and Identification.** *K. pneumoniae* NB5306 was recovered from a blood culture from a 72-year-old female patient. The patient hospitalized (Day 0) in hematology ward in Ningbo First Hospital, China, with the history of aplastic anemia. In order to prevent nosocomial infection, ceftriaxone/sulbactam (3 g q8 h) was administered after admission for 2 days, and then administration was changed to biapenem (0.3 g q8 h) for 10 days; the patient was stable and had no invasive procedure. However, the patient had a fever at Day 20, and the highest temperature was up to 40°C, with white blood cell count being  $0.60 \times 10^9/L$ , neutrophil% 20.0%, and c-reactive protein (CRP) 37.20 mg/L. Blood culture was examined immediately on Day 20, and the empiric therapy was administered with imipenem (0.5 g q6 h), vancomycin (0.5 g q12 h), and voriconazole (0.2 g q12 h). During the treatment, the temperature of patient was sustained, and her condition continued to deteriorate; therefore, the patient gave up further treatment on Day 22 and returned home. Unfortunately, we were informed that the patient died at home two days after discharge by phone follow-up. *K. pneumoniae* NB5306 was recovered from blood culture and was identified with VITEK® 2 automated microbial identification system.

**2.2. Antimicrobial Susceptibility Testing.** Antimicrobial susceptibility testing of MICs was performed by the agar dilution method or broth microdilution method (for tigecycline and colistin), with susceptibility defined according to Clinical and Laboratory Standards Institute (CLSI) (M100-S28) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) (version 8.1, for tigecycline and colistin) guidelines.

**2.3. Genome Sequencing and Bioinformatics Analysis.** The genomic DNA was extracted by QIAamp DNA Mini Kit (Qiagen, Germany) and sent to Zhejiang Tianke Hi-tech Development Co., Ltd. (Tianke, Hangzhou, China) for library preparation and genome sequencing. Genome was

sequenced by HiSeq instrument (Illumina, San Diego, CA, USA). Reads were *de novo* assembled using CLC Genomics Workbench (version 9.5.1). Multilocus sequence typing (MLST) was identified by the genome sequence using MLST 2.0 (<https://cge.cbs.dtu.dk/services/MLST/>). The antimicrobial resistome was identified using ResFinder 3.1 (<https://cge.cbs.dtu.dk/services/ResFinder/>). Mutations in two outer membrane porin-encoding genes *ompK35* and *ompK36* were determined using KX528043.1 and JX291114.1 as references, respectively.

**2.4. Plasmid Conjugation and Chemical Transformation.** Plasmid conjugation of the *bla*<sub>OXA-232</sub> gene was attempted by conjugation experiments at 37°C using rifampicin-resistant *E. coli* EC600 or sodium azide-resistant *E. coli* J53 as recipient, and imipenem (0.12 mg/L) associated with rifampicin (700 mg/L) or sodium azide (300 mg/L) was used for selection.

The chemical transformation was performed when conjugation failed. Plasmid harboring *bla*<sub>OXA-232</sub> gene was transferred into *E. coli* DH5 $\alpha$  by chemical transformation with imipenem (0.12 mg/L) for selection. The MICs of NB5306-D (DH5 $\alpha$  chemical transformant of NB5306) to ertapenem, meropenem, and imipenem were performed.

**2.5. S1 PFGE and Southern Bolt.** Genomic DNA was digested with S1-nuclease (Takara, Otsu, Japan) and electrophoresed on a PFGE system (Bio-Rad, Hercules, CA, USA) for 10 h at 14°C, with run conditions of 6 V/cm and pulse times from 2.16 s to 63.8 s. DNA fragments were transferred to a positively charged nylon membrane (Millipore, Billerica, MD, USA) and then hybridized with a digoxigenin-labelled *bla*<sub>OXA-232</sub>-specific probe. The fragments then were detected with an NBT/BCIP color detection kit (Roche, Mannheim, Germany).

**2.6. The Primer Walking Sequencing.** The plasmid containing *bla*<sub>OXA-232</sub> was obtained by Axygen plasmid miniprep (Axygen Biosciences, USA), initial round of sequencing was from a known sequence at one end of the template, and initial primers were *bla*<sub>OXA-48-F</sub> (5'-ATGCGTGTAT-TAGCCTTATCGGCT-3') and *bla*<sub>OXA-48-R</sub> (5'-CTAGG-GAATAATTTTTCTCTGTTGAG-3'); then, each subsequent round was initiated from a new primer, which is based on the end of the sequence obtained from the previous reaction. Finally, the full length of the plasmid was sequenced after some rounds of reactions. The replicon of plasmid was identified by plasmid finder 2.1 (<https://cge.cbs.dtu.dk/services/PlasmidFinder/>).

## 3. Results

**3.1. Results of Antimicrobial Susceptibility Testing and MLST.** NB5306 was resistant to ertapenem (MIC of 8 mg/L) but susceptible to imipenem (MIC of 0.25 mg/L), intermediate to meropenem (MIC of 2 mg/L). Moreover, NB5306 was susceptible to fosfomycin, tigecycline, and colistin but

TABLE 1: *In vitro* activities of antimicrobial agents against *K. pneumoniae* NB5306 and their transformants.

| Strain<br>$\beta$ -Lactamase (s) | NB5306                                   | NB5306-D | <i>E. coli</i> DH5 $\alpha$ | KP1-T [8]                       | KP1 [8] |
|----------------------------------|--|----------|-----------------------------|---------------------------------|---------|
|                                  | OXA-232, TEM-1B, SHV-11,<br>and CTX-M-55 | OXA-232  | OXA-232                     | OXA-232, SHV-1,<br>and CTX-M-15 |         |
| Ertapenem                        | 8  | 1        | 0.03                        | 0.25                            | 32      |
| Meropenem                        | 2  | 0.12     | 0.03                        | 0.12                            | 4       |
| Imipenem                         | 0.25                                     | 0.5      | 0.06                        | 2                               | 1       |
| Cefotaxime                       | 128                                      |          |                             |                                 |         |
| Ceftriaxone                      | 256                                      |          |                             |                                 |         |
| Piperacillin/tazobactam          | 256                                      |          |                             |                                 |         |
| MIC<br>(mg/L)                    |  |          |                             |                                 |         |
| Amikacin                         | 256                                      |          |                             |                                 |         |
| Gentamicin                       | 256                                      |          |                             |                                 |         |
| Tobramycin                       | 32                                       |          |                             |                                 |         |
| Ciprofloxacin                    | 32                                       |          |                             |                                 |         |
| Levofloxacin                     | 32                                       |          |                             |                                 |         |
| Fosfomycin                       | 8  |          |                             |                                 |         |
| Colistin                         | 0.03                                     |          |                             |                                 |         |
| Tigecycline                      | 0.25                                     |          |                             |                                 |         |

NB5306: *K. pneumoniae* NB5306; NB5306-D: DH5 $\alpha$  chemical transformant of NB5306; KP1-T: DH5 $\alpha$  electrotransformant of *K. pneumoniae* KP1; KP1 = *K. pneumoniae* KP1.




FIGURE 1: S1-PFGE and Southern blot of isolates. H9812: *Salmonella* H9812 molecular marker; NB5306: *K. pneumoniae* NB5306; KP1-T: DH5 $\alpha$  electrotransformant of *K. pneumoniae* KP1; NB5306-D: DH5 $\alpha$  chemical transformant of *K. pneumoniae* NB5306.

resistant to other  $\beta$ -lactams or  $\beta$ -lactams/ $\beta$ -lactamase inhibitor (cefotaxime, ceftriaxone, and piperacillin/tazobactam), aminoglycosides (gentamicin, tobramycin, and amikacin), as well as fluoroquinolones (ciprofloxacin and levofloxacin). NB5306 was identified as ST437 (*gapA* 3,

*infB3*, *mdh* 1, *pgi* 1, *phoE* 1, *rpoB* 1, and *tonB* 31), with one housekeeper gene difference with ST11 (*gapA* 3, *infB3*, *mdh* 1, *pgi* 1, *phoE* 1, *rpoB* 1, and *tonB* 1).

3.2. *Results of Antimicrobial Resistome.* The antimicrobial resistome was comprised of genes conferring resistance to  $\beta$ -lactams (*bla*<sub>OXA-232</sub>, *bla*<sub>CTX-M-55</sub>, *bla*<sub>TEM-1b</sub>, and *bla*<sub>SHV-11</sub>), aminoglycosides (*aph* (3')-IIa, *aph* (3'')-Ib, *aph* (6)-Id, and *rmtB*), fluoroquinolones (*oqxA* and *oqxB*), fosfomycin (*fosA*), trimethoprim (*dfrA14*), sulphonamide (*sul2*), phenicol (*floR*), and tetracycline (*tetA*).

3.3. *Results of Plasmid Conjugation and Chemical Transformation.* NB5306 carried a wild-type *ompK35* but a novel *ompK36* variant, a highly conserved domain within the region of loop 3 (DVLPEFGD TDTYGF DNFLQSR ANGV).

In the conjugation experiments, *bla*<sub>OXA-232</sub> was unsuccessfully transferred to EC600 and J53. MICs of NB5306-D (DH5 $\alpha$  chemical transformant of NB5306) to ertapenem, meropenem, and imipenem rose to 1 mg/L, 0.12 mg/L, and 0.5 mg/L, respectively, which was higher than the MICs of *E. coli* DH5 $\alpha$  (ertapenem 0.03 mg/L, meropenem 0.03 mg/L, and imipenem 0.06 mg/L, respectively) (Table 1).

3.4. *Results of S1 PFGE and Plasmid Sequencing.* S1 PFGE and Southern blot showed that *bla*<sub>OXA-232</sub> gene was located on ~6 kb plasmid (Figure 1), and *bla*<sub>OXA-232</sub> gene was located on a 6141 bp plasmid by primer walking sequencing.

The plasmid differs from the plasmid (GenBank accession no. KY454616) found in Shanghai with one nucleotide substitution [2], which contained nine open reading frames (MobA, MobB, MobD,  $\Delta$ MobC,  $\Delta$ ISEcp1, *bla*<sub>OXA-232</sub>,  $\Delta$ LysR,  $\Delta$ EreA, and RepA). Plasmid finder revealed the *bla*<sub>OXA-232</sub> gene was on a ColKP3-type plasmid.

#### 4. Discussion

The OXA-232 carbapenemase-producing strains emerging had been frequently reported to have association with travelling to India. For example, Potron et al. reported that two *K. pneumoniae* and one *E. coli* harboring OXA-232 were recovered from three patients transferred from India to France in 2011 [7]. Findlay et al. reported that OXA-232 was found in isolates from patients reporting travel to India across the UK between 2007 and 2014 [10]. Jeong et al. reported that clonal and horizontal spread of the *bla*<sub>OXA-232</sub> gene among *Enterobacteriaceae* in a Korean hospital was attributed to an index patient who was likely colonized during a prior hospitalization in India [11]. But some reported OXA-232 strains were not strongly relevant to the history of recent travel abroad. For example, Mancini et al. reported that 6 *K. pneumoniae* were recovered in 2017 from 5 different patients, who reported no recent travel abroad [12]. Abdul Momin et al. reported that 5 OXA-232-producing *K. pneumoniae* isolates were recovered from 5 patients in Brunei; all patients were hospitalized locally and had no history of recent travel [13]. In this study, the patient was hospitalized locally and reported no travel abroad history.

Previously reports showed that the dominant epidemic ST in *bla*<sub>OXA-232</sub> *K. pneumoniae* belonged to ST14 (France [7], the United States [14, 15], South Korea [11], and Middle East [16]), ST15 (China [2, 3] and Czech Republic [17]), ST16 (USA [14], Italy [18], and UK [10]), ST147 (India [19], Tunisia [20], and UK [10]), ST231 (Switzerland [12], the UK [10], Poland [21], Singapore [22], and Brunei Darussalam [13]), and ST395 (India [19] and UK [10]). Moreover, ST11 (India [19]) and hypervirulent ST23 (India [23]) OXA-232-producing *K. pneumoniae* have also been sporadically identified. In this research, we identified an OXA-232-producing strain belonging to ST437. ST437 belonged to clonal complex 11 (CC11), which was together with its single-locus variants ST11 and ST258 [24]. The high-risk multidrug-resistant CC11 is widespread worldwide, and cases with the CC11 strain faced more severe forms of drug resistance and treatment challenges than other clonal complex [8], especially KPC-producing and NDM-producing CC11. Among CC11, ST258 CRKP predominated in North America and Europe [25]; furthermore, ST11 was the primary CRKP clone in eastern Asia, especially in China [1]. What interested us was that we identified an OXA-232-producing CC11 isolates in China, which indicated that the OXA-48-type carbapenemase was spreading in high-risk CC11, like KPC and NDM.

*bla*<sub>OXA-232</sub> *K. pneumoniae* was found in France [7] and China [2], and this study remained susceptible to colistin and tigecycline, but NB5306 showed different drug resistance profiles to carbapenems compared with strain RAN, which was the first *K. pneumoniae* strain harboring *bla*<sub>OXA-232</sub> [7], with NB5306 MICs of ertapenem was 8 mg/L, imipenem was 0.25 mg/L, and meropenem was 2 mg/L, while RAN was resistant to ertapenem, imipenem, and meropenem, with MIC >32 mg/L [7]. NB5306-D obtained *bla*<sub>OXA-232</sub> by chemical transformation, and the MIC of ertapenem was 1 mg/L, in which we conjectured that the

*ompK36* variant might play a role in charge of MIC of ertapenem [26].

Among studies involving OXA-232, only Jeong et al. reported that the *bla*<sub>OXA-232</sub> gene was located on a conjugative ColE-type plasmid 6141 bp in size, and this plasmid was successfully transferred from *K. pneumoniae* H16 to *E. coli* J53 by conjugation [11]. However, this investigation and other studies reported that *bla*<sub>OXA-232</sub> gene was located on a nonconjugative ColKP3-type plasmid 6141 bp in size [3, 7, 22]. Nonconjugative plasmids are incapable of initiating conjugation; however, they can be transferred with the assistance of conjugative plasmids. The same kind of 6 kb plasmids harboring *bla*<sub>OXA-232</sub> were also found in Europe, North America, Asia, and North Africa [20]. It is speculated that 6 kb plasmid is likely disseminated in the whole world.

The study provides the emergence of an OXA-232 *K. pneumoniae* belonging to CC11. Further surveillance and investigations are needed to have better understanding of potential transmission and evolution of OXA-232 carbapenemase-producing CRKP in the world.

#### Data Availability

The draft genome sequence of *K. pneumoniae* NB5306 and the complete nucleotide sequence of the plasmid carrying *bla*<sub>OXA-232</sub> have been deposited in GenBank under accession numbers QYCO00000000 and MK105834, respectively.

#### Ethical Approval

We obtained the approval letter of Ningbo First Hospital Ethics Committee (Approval no. 2019-R044). Institutional approval was obtained by Clinical Research Management Committee of Ningbo First Hospital to publish the case details.

#### Consent

Written informed consent was obtained from the patient's son.

#### Conflicts of Interest

The authors declare that they have no conflicts of interest.

#### Authors' Contributions

Xingbei Weng and Qiucheng Shi contributed equally to this work.

#### Acknowledgments

The plasmid of isolate KP1 was obtained from Dr. Fupin Hu as a gift. This work was supported by the Key Research and Development Programme of Zhejiang (2015C03046), National Natural Science Foundation of China (8183009), Ningbo Natural Science Foundation (2019A610381), and Ningbo Public Welfare Foundation (2019C50087).

## References

- [1] R. Zhang, L. Liu, H. Zhou et al., "Nationwide surveillance of clinical carbapenem-resistant *Enterobacteriaceae* (CRE) strains in China," *EBioMedicine*, vol. 19, pp. 98–106, 2017.
- [2] D. Yin, D. Dong, K. Li et al., "Clonal dissemination of OXA-232 carbapenemase-producing *Klebsiella pneumoniae* in neonates," *Antimicrob Agents Chemother*, vol. 61, no. 8, pp. e00385–17, 2017.
- [3] L. Shu, N. Dong, J. Lu et al., "Emergence of OXA-232 carbapenemase-producing *Klebsiella pneumoniae* that carries a pLVPK-like virulence plasmid among elderly patients in China," *Antimicrobial Agents and Chemotherapy*, vol. 63, no. 3, pp. e02246–18, 2019.
- [4] L. Guo, J. An, Y. Ma et al., "Nosocomial outbreak of OXA-48-producing *Klebsiella pneumoniae* in a Chinese hospital: clonal transmission of ST147 and ST383," *PLoS One*, vol. 11, no. 8, Article ID e0160754, 2016.
- [5] L. Poirel, C. Héritier, V. Tolün, and P. Nordmann, "Emergence of oxacillinase-mediated resistance to imipenem in *Klebsiella pneumoniae*," *Antimicrobial Agents and Chemotherapy*, vol. 48, no. 1, pp. 15–22, 2004.
- [6] D. Johann, G. Peirano, M. M. Kock et al., "The global ascendancy of OXA-48-type carbapenemases," *Clinical Microbiology Reviews*, vol. 33, no. 1, pp. e00102–19, 2019.
- [7] A. Potron, E. Rondinaud, L. Poirel et al., "Genetic and biochemical characterisation of OXA-232, a carbapenem-hydrolysing class D  $\beta$ -lactamase from *Enterobacteriaceae*," *International Journal of Antimicrobial Agents*, vol. 41, no. 4, pp. 325–329, 2013.
- [8] L. Yin, L. He, J. Miao et al., "Active surveillance and appropriate patient placement in contact isolation dramatically decreased carbapenem-resistant *Enterobacteriales* infection and colonization in paediatric patients in China," *Journal of Hospital Infection*, vol. 105, no. 3, pp. 486–494, 2020.
- [9] X. Zhang, W. Wang, H. Yu et al., "New Delhi metallo- $\beta$ -lactamase 5-producing *Klebsiella pneumoniae* sequence type 258, southwest China, 2017," *Emerging Infectious Diseases*, vol. 25, no. 6, pp. 1209–1213, 2019.
- [10] J. Findlay, K. L. Hopkins, R. Loy et al., "OXA-48-like carbapenemases in the UK: an analysis of isolates and cases from 2007 to 2014," *Journal of Antimicrobial Chemotherapy*, vol. 72, no. 5, pp. 1340–1349, 2017.
- [11] S. H. Jeong, K. M. Lee, J. Lee et al., "Clonal and horizontal spread of the bla OXA-232 gene among *Enterobacteriaceae* in a Korean hospital," *Diagnostic Microbiology and Infectious Disease*, vol. 82, no. 1, pp. 70–72, 2015.
- [12] S. Mancini, L. Poirel, M. L. Tritten et al., "Emergence of an MDR *Klebsiella pneumoniae* ST231 producing OXA-232 and RmtF in Switzerland," *Journal of Antimicrobial Chemotherapy*, vol. 73, no. 3, pp. 821–823, 2018.
- [13] M. H. F. Abdul Momin, A. Liakopoulos, L. M. Phee, and D. W. Wareham, "Emergence and nosocomial spread of carbapenem-resistant OXA-232-producing *Klebsiella pneumoniae* in Brunei Darussalam," *Journal of Global Antimicrobial Resistance*, vol. 9, pp. 96–99, 2017.
- [14] J. D. Lutgring, W. Zhu, T. J. B. de Man et al., "Phenotypic and genotypic characterization of *Enterobacteriaceae* Producing oxacillinase-48-like carbapenemases, United States," *Emerging Infectious Diseases*, vol. 24, no. 4, pp. 700–709, 2018.
- [15] Y. Doi, J. A. O'Hara, J. F. Lando et al., "Co-Production of NDM-1 and OXA-232 by *Klebsiella pneumoniae*," *Emerging Infectious Diseases*, vol. 20, no. 1, pp. 163–165, 2014.
- [16] A. E. Al-Baloushi, T. Pál, A. Ghazawi, and A. Sonnevend, "Genetic support of carbapenemases in double carbapenemase producer *Klebsiella pneumoniae* isolated in the Arabian Peninsula," *Acta Microbiologica et Immunologica Hungarica*, vol. 65, no. 2, pp. 135–150, 2018.
- [17] A. Skalova, K. Chudejova, V. Rotova et al., "Molar characterization of OXA-48-like-producing *Enterobacteriaceae* in the Czech Republic and evidence for horizontal transfer of pOXA-48-like plasmids," *Antimicrobial Agents and Chemotherapy*, vol. 61, no. 2, pp. e01889–16, 2017.
- [18] P. Espinal, E. Nucleo, M. Caltagirone et al., "Genomics of *Klebsiella pneumoniae* ST16 producing NDM-1, CTX-M-15, and OXA-232," *Clinical Microbiology and Infection*, vol. 25, no. 3, pp. e1–e5, 2019.
- [19] C. Shankar, P. Mathur, M. Venkatesan et al., "Rapidly disseminating blaOXA-232 carrying *Klebsiella pneumoniae* belonging to ST231 in India: multiple and varied mobile genetic elements," *BMC Microbiology*, vol. 19, no. 1, p. 137, 2019.
- [20] H. Lahlaoui, R. A. Bonnin, M. B. Moussa, A. B. H. Khelifa, and T. Naas, "First report of OXA-232-producing *Klebsiella pneumoniae* strains in Tunisia," *Diagnostic Microbiology and Infectious Disease*, vol. 88, no. 2, pp. 195–197, 2017.
- [21] R. Izdebski, A. Baraniak, D. Żabicka et al., "Enterobacteriaceae producing OXA-48-like carbapenemases in Poland, 2013–January 2017," *Journal of Antimicrobial Chemotherapy*, vol. 73, no. 3, pp. 620–625, 2018.
- [22] J. W. P. Teo, A. Kurup, R. T. P. Lin, and K. T. Hsien, "Emergence of clinical *Klebsiella pneumoniae* producing OXA-232 carbapenemase in Singapore," *New Microbes and New Infections*, vol. 1, no. 1, pp. 13–15, 2013.
- [23] S. Mukherjee, S. Naha, P. Bhadury et al., "Emergence of OXA-232-producing hypervirulent *Klebsiella pneumoniae* ST23 causing neonatal sepsis," *Journal of Antimicrobial Chemotherapy*, vol. 75, no. 7, pp. 2004–2006, 2020.
- [24] P. S. Pereira, C. F. M. de Araujo, L. M. Seki et al., "Update of the molecular epidemiology of KPC-2-producing *Klebsiella pneumoniae* in Brazil: spread of clonal complex 11 (ST11, ST437 and ST340)," *Journal of Antimicrobial Chemotherapy*, vol. 68, no. 2, pp. 312–316, 2013.
- [25] L. Chen, B. Mathema, K. D. Chavda, F. R. DeLeo, R. A. Bonomo, and B. N. Kreiswirth, "Carbapenemase-producing *Klebsiella pneumoniae*: molecular and genetic decoding," *Trends in Microbiology*, vol. 22, no. 12, pp. 686–696, 2014.
- [26] F. M. Kaczmarek, F. Dib-Hajj, W. Shang, and T. D. Gootz, "High-level carbapenem resistance in a *Klebsiella pneumoniae* clinical isolate is due to the combination of blaACT-1  $\beta$ -lactamase production, porin OmpK35/36 insertional inactivation, and down-regulation of the phosphate transport porin PhoE," *Antimicrobial Agents and Chemotherapy*, vol. 50, no. 10, pp. 3396–3406, 2006.